Inozyme Pharma Inc (INZY)

INZY cashed out on Wednesday @ $4 due to merger, at least I didn't lose everything.

Nope…🥳

You get any of this

INZY...$1.52...🥳... https://schrts.co/DXWCIncw ...Reversal setting up here on this Oversold Chart...

Most Recent News...https://www.globenewswire.com/news-release/2025/01/10/3007647/0/en/Inozyme-Pharma-Announces-Positive-Interim-Data-for-INZ-701-in-Infants-and-Young-Children-with-ENPP1-Deficiency-and-Key-Program-Updates.html

Taking a beating this week. 

INZY under $6

$INZY - 👆Up 7% Pre-Market/ Current Price $5.12
Pivotal bioVenture Partners Fund I, L.P purchases
835k shares equal to $4m investment

INZY new 52 week high

Loading

Have a feeling this about to squeeze into a halt soon…..

Great week so far. Gotta keep it movin.

Quietest board out there

Grabbed a starter here today

INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.

Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

(i) Deep Track Capital, LP

(ii) Deep Track Biotechnology Master Fund, Ltd.

(iii) David Kroin

INZY

I like the BioXc chart looks better. Thanks for all the good insight.

The offering is expected to close on or about April 19, 2022

This analyst know about the offering?
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.

PT > 33.00

H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.